Progen
Seoul
About Progen
Progene is an R&D-focused biopharmaceutical development venture that has maintained continuous collaboration and partnerships with the top pharmaceutical companies. Progene’s platform technology is a multi-target fusion protein technology, and it aims to discover various new drug candidates using this technology and create value and achieve continuous growth through joint development or external technology transfer.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Total funding: $15.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Apr 2025)
- Ticker: krx:296160
- Website: progen.co.kr
- Phone: 82-2-6098-2800
Industries & Categories
Pharmaceutical, Therapeutics
Canonical: https://fsome.com/organization/progen-33541 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.